Canada - français - Health Canada

jamp pharma corporation - tofacitinib (citrate de tofacitinib) - comprimé - 5mg - tofacitinib (citrate de tofacitinib) 5mg

Union européenne - français - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - arthrite, rhumatoïde - immunosuppresseurs - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant peut être utilisé en monothérapie ou en association avec le méthotrexate. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Union européenne - français - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - arthrite, rhumatoïde - immunosuppresseurs - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 et 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - pemigatinibum - comprimés - pemigatinibum 4.5 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 0.176 mg, magnesii stearas, pro compresso. - cholangiocarcinome - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - pemigatinibum - comprimés - pemigatinibum 9 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 0.352 mg, magnesii stearas, pro compresso. - cholangiocarcinome - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

incyte biosciences international sàrl - pemigatinibum - comprimés - pemigatinibum 13.5 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 0.528 mg, magnesii stearas, pro compresso. - cholangiocarcinome - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tofacitinibum - comprimés pelliculés - tofacitinibum 5 mg à tofacitinibi citras, excipiens pro compresso de la brume. - immunosuppresseur sélectif - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tofacitinibum - comprimés pelliculés - tofacitinibum 10 mg à tofacitinibi citras, color.: e 132, e 133, excipiens pro compresso de la brume. - immunosuppresseur sélectif - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - gefitinibum - comprimés pelliculés - gefitinibum 250 mg, lactosum monohydricum 163.5 mg, cellulosum microcristallinum, carmellosum natricum conexum, povidonum k 29-32, natrii laurilsulfas, magnesii stearas, Überzug: hypromellosum, macrogolum 300, e 171, e 172 (rubrum), e 172 (flavum), pro compresso obducto corresp. natrium 2.02 mg. - cytostatique - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - baricitinibum - comprimés pelliculés - comprimé pelliculé: baricitinibum 2 mg, mannitolum 52 mg, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, pellicule: poly(alcohol vinylicus), macrogolum, talcum, lecithinum ex soja, e 171, e 172 (rubrum), pro compresso obducto, natrium 0.7608 mg. - polyarthrite rhumatoïde / dermatite atopique / covid 19 / alopecia areata - synthetika